Longevity
Peptides
Compound profile

Metformin: Biguanide and Longevity Trial

Metformin is the most-prescribed type 2 diabetes drug globally, being investigated in the TAME trial for age-related disease outcomes.

On this page

What it is

Metformin is a biguanide antidiabetic drug derived from galegine. FDA-approved since 1995 for type 2 diabetes. Extensive clinical experience including in non-diabetic populations.

Evidence snapshot

Category: Longevity. Status: Human Trials. See the references section below for the underlying primary sources.

Mechanism

Primary mechanism is suppression of hepatic gluconeogenesis via AMPK activation and mitochondrial complex I inhibition. Additional effects on inflammation and cellular stress responses.

Key research findings

Observational studies in diabetic populations have suggested reductions in age-related disease incidence. The TAME trial is the first major RCT designed to test metformin in non-diabetic age-related outcomes.

Limits of the evidence

Observational data subject to confounding by indication. TAME trial pending completion. GI side effects are common.

Continue reading

Tissue Repair

BPC-157

Synthetic pentadecapeptide derived from a gastric juice protein, studied across hundreds of preclinical reports for tissue regeneration and cytoprotection.
Read Guid
Tissue Repair

TB-500 (Thymosin Beta-4 fragment)

Synthetic fragment of Thymosin Beta-4, a 43-amino-acid peptide investigated for its role in actin regulation, cell migration, and wound healing.
Read Guid
Peptide Protocols

BPC-157 + TB-500

Combined tissue-repair peptides with complementary mechanisms — the synergy hypothesis examined critically against the available preclinical record.
Read Guid
Growth Hormone · Research

Ipamorelin

Selective pentapeptide agonist of the growth hormone secretagogue receptor (GHSR-1a) studied for targeted GH release with minimal effect on cortisol, ACTH and prolactin.
Read Guid